Krystal Biotech share price today

Krystal Biotech, Inc.'s share price was $310.84 at the close on 4 November 2026. It has been rising for 44 weeks. That is 0.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between $198 and $375, and at that close it sat 64% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Krystal Biotech, Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running.

Over the last 9.1 years the share price moved +2,990% while the S&P 500 moved +207%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Krystal Biotech, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Krystal Biotech is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Krystal Biotech, Inc. earned $54.8 M of net profit in the Jun 2026 quarter, +42.9% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY25 profit was $205 M. Over 2 years profit has grown 332.9% a year on average. That is 45.9% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned $38.3 M.

For the full year, FY25 profit was $205 M (+129.7% on the year before).

Why profit moved: revenue changed +24.1% on a year earlier and the margin moved +8.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +76.1% and revenue +22.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

Krystal Biotech, Inc. reported $119 M of revenue in the Jun 2026 quarter, +24.1% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 2 years it has grown 177.0% a year on average. The last full year, FY25, came in at $389 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $440 M.

FY25 revenue was $389 M, +33.9% on the year before.

Recent pace: the last four quarters grew +22.5% on average, against 177.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +22.6%, against +62.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +64.6%, against +51.0% a year (accelerating).

Krystal Biotech, Inc.'s operating margin was 49.0% in the Jun 2026 quarter, 8.0 percentage points higher than the same quarter a year ago. Across 3 years it has been between −191.6% and 41.5%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +8.0 percentage points on the year while gross margin changed +2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 77% of Krystal Biotech, Inc.'s reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $201 M of operating cash against $205 M of profit. After $12.0 M of spending on assets, $189 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Krystal Biotech, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $28.0 M on assets over the last 3 years. Averaged over those years that is 2.4% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $28.0 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Krystal Biotech, Inc.'s P/E is 42.2×, in the middle of its own history: higher than 59% of past readings. Its usual P/E (the middle reading) is 40.9×, over 2.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +128.0% while the price moved +57.0%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Krystal Biotech, Inc.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 16.3%; each line tells part of the story. This is based on 8 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Krystal Biotech, Inc. earned a ROE of 17% in FY25. That is up from a low of 1% in FY23. Its return on capital used (ROIC) is 29.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 52.6% net margin and 0.29× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 52.6% net margin × 0.29× asset turnover × 1.09× leverage (assets divided by equity) ≈ 16.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 37.5% − 7.8% = +29.7 percentage points. The 7.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 37.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 42.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Krystal Biotech, Inc. has total debt of $8.9 M against shareholder equity of $1.4 B as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.